CAR-T cell therapy cost in Turkey

CAR-T cell therapy cost in Turkey by product access, manufacturing, and clinical pathway

CAR-T is a complex, product-specific cellular therapy, not a routine infusion. Before travel, the treating center must confirm the exact blood-cancer indication, prior treatment, antigen and disease status, organ and infection fitness, authorized product or clinical-study route, manufacturing slot, cell-collection plan, expected turnaround, bridging therapy, lymphodepleting chemotherapy, accredited inpatient service, intensive-care backup, and long-term follow-up. A projected price is never proof that the product is currently available.

How much can CAR-T cell therapy cost in Turkey?

Where an eligible product-specific CAR-T pathway can actually be confirmed, a prudent Turkey planning range is approximately TRY 5,170,000 to 8,460,000 (about USD 110,000 to 180,000). Complex bridging treatment, manufacturing delay or failure, prolonged admission, severe cytokine release syndrome or neurologic toxicity, ICU care, infection, transfusions, and extended local monitoring can move the total above TRY 9,400,000 (USD 200,000+). Availability, regulatory route, manufacturing, and hospital authorization must be verified in writing before travel or payment.

USD illustrations use about TRY 47 per USD, near the official indicative selling rate on 17 July 2026. Cellular products and manufacturing may be contracted in EUR or USD. Confirm the product, manufacturer, regulatory or trial route, taxes, refund and cancellation terms, exchange rule, and quote expiration.

Review cost scenarios Upload reports

Let Us Help You

Share the basics and the Virello team will guide you toward the next step.

Prefer email? Write to support@virellohealth.com.

Patient Name

Country

Phone Number

Describe The Current Medical Problem

Reviewed 2026-07-19

Clinical review: Virello Health Clinical Content Team · Editorial review: Virello Health Research Team

Billing context: TRY and USD

Availability must be proven

A website, coordinator message, or projected quote does not confirm that a specific CAR-T product is authorized, supplied, and deliverable for the diagnosis at that hospital.

The patient’s own cells begin the process

For autologous products, T cells are collected by apheresis, shipped and modified, quality tested, returned, and infused after conditioning treatment.

Manufacturing takes time

Commercial production commonly requires several weeks, during which disease may need bridging treatment and eligibility can change.

CRS and neurotoxicity need specialist rescue

Fever, low blood pressure, low oxygen, confusion, language change, seizure, or reduced consciousness can require rapid protocol-led treatment and intensive care.

Cost at a glance

Planning scenarios for car-t cell therapy in Turkey

The scenarios separate routine and complex pathways. They are not fixed packages and should be replaced by a report-led hospital estimate before travel.

Estimated car-t cell therapy cost scenarios in Turkey
Scenario	TRY	USD	Patient and treatment context	Planning scope
Eligible pathway without major complication	TRY 5,170,000 - 6,580,000	USD 110,000 - 140,000	A confirmed eligible hematologic cancer with product access, successful apheresis and manufacturing, limited bridging, standard lymphodepletion, expected admission, and no ICU-level toxicity.	Must itemize product and manufacturing, collection, cryopreservation and shipping, bridging allowance, lymphodepletion, infusion, inpatient monitoring, routine supportive care, and initial follow-up.
Higher-complexity standard pathway	TRY 6,580,000 - 8,460,000	USD 140,000 - 180,000	A patient requiring more extensive restaging, bridging, infection treatment, transfusion support, longer ward monitoring, or management of moderate toxicity.	Add the named bridge regimen, extra laboratory and imaging work, blood products, antimicrobials, extended room days, toxicity medicines, and post-discharge lodging.
Severe toxicity or prolonged course	TRY 8,460,000 - 9,400,000+	USD 180,000 - 200,000+	Manufacturing or disease-control complications, severe cytokine release syndrome, neurotoxicity, ICU care, organ support, prolonged low counts, serious infection, or delayed discharge.	No fixed ceiling is responsible; obtain ward and ICU daily rates, high-cost rescue medicines, organ support, repeat procedures, and manufacturing cancellation terms.

Usually included

Check the clinical package scope

Named cellular product

Commercial or study product, target, manufacturer or sponsor, regulatory pathway, manufacturing slot, release criteria, and the product charge.

Confirm what happens financially if cells cannot be collected, manufactured, released, or infused.

Apheresis and cell logistics

Collection procedure, line if required, laboratory handling, cryopreservation, courier, chain of identity and custody, and shipment stated in the contract.

Cross-border cell movement requires documented responsibility.

Lymphodepletion and infusion

Named conditioning medicines, laboratory clearance, pharmacy, cellular infusion, observation, routine supportive medicines, and the planned inpatient episode.

Bridging therapy occurs earlier and may be separate.

Specified monitoring period

Defined ward days, routine blood tests, infection precautions, toxicity scoring, early disease assessment, and post-discharge visits.

ICU and prolonged cytopenia may exceed the allowance.

Confirm separately

Charges that may sit outside the range

Eligibility and restaging work

Expert pathology, antigen or molecular confirmation, marrow tests, PET-CT or other imaging, organ evaluation, infectious-disease testing, and donor or transplant review unless named.

Eligibility can change before collection or infusion.

Bridging therapy

Chemotherapy, targeted treatment, immunotherapy, radiation, steroids, procedures, transfusions, or admission used to control disease during manufacturing.

Ask which options preserve CAR-T feasibility.

Severe toxicity treatment

ICU, vasopressors, oxygen or ventilation, anti-cytokine medicines, steroids, seizure care, dialysis, procedures, and prolonged specialists.

Obtain uncapped rates and rescue-drug pricing.

Long-term complications and follow-up

Prolonged low blood counts, immunoglobulin, antivirals and antibiotics, vaccines, infection admission, marrow evaluation, relapse treatment, and years of surveillance.

Home access is part of candidate planning.

Candidate context

Who may be considered and what else may be discussed

CAR-T suitability is product and indication specific. Review usually includes confirmed hematologic diagnosis and target expression where relevant, disease status and burden, previous lines and response, available alternatives, speed of progression, marrow reserve, organ function, performance, active infection, viral screening, neurologic history, prior transplant, immune status, pregnancy, caregiver support, proximity to the treating center, and ability to complete long-term surveillance. The cellular-therapy program, not a travel intermediary, must issue the eligibility and access decision.

Information that shapes suitability

Product-specific disease criteria

Cancer subtype, age, previous treatments, relapse or refractory status, target and regulatory indication must match the exact proposed product or trial.

Fitness for collection and toxicity

Vascular access, blood counts, kidney, liver, heart, lung, neurologic status, infection control, and functional reserve affect safety.

Disease control during manufacturing

The team assesses whether the cancer can remain controlled during the collection-to-infusion interval and which bridge is least likely to compromise the pathway.

Caregiver and geographic readiness

A trained adult, nearby accommodation, rapid hospital access, communication, financial reserve, and home hematology support may be mandatory.

Alternatives or sequencing questions

Standard salvage or targeted therapy

Chemotherapy, antibody, targeted, immune, or disease-specific combinations may offer a faster or more established route according to biology and prior treatment.

Stem-cell transplant

Autologous or allogeneic transplant can remain appropriate in selected diseases and responses, with distinct donor, conditioning, toxicity, and follow-up needs.

Clinical trial

A study may provide access to another cellular product or mechanism, but eligibility, allocation, travel, research costs, and post-study obligations must be clear.

Supportive and palliative care

When disease, fitness, access, or expected benefit makes cellular therapy unsuitable, symptom control and patient-prioritized care should be discussed honestly.

Procedure variations

Why the named procedure does not have one price

Technique, device, medicine, treatment extent, and prior care can change both the clinical plan and the estimate.

Commercial autologous CAR-T

The patient’s cells are collected and manufactured into a named licensed product for a defined indication.

Confirm local authorization, manufacturer supply, and center certification.

Clinical-study cellular therapy

Treatment is delivered under a research protocol with specific inclusion criteria, consent, tests, schedule, and follow-up.

Clarify covered research costs and patient-paid clinical costs.

Bridged pathway

Disease-directed treatment is given after collection or during manufacturing to maintain control until infusion.

Price it separately and document its effect on timing and eligibility.

Alternative target or later-line product

Different blood cancers and prior exposures may require another antigen target or product with different evidence and risks.

Do not assume one CAR-T price applies to all diseases.

City comparison

Cost and capability by city in Turkey

Only cities with evidence for the procedure should appear here. A city range does not prove that every hospital in that city can manage the same case complexity.

Estimated car-t cell therapy costs and planning context by city in Turkey
City	Local range	USD range	Capability context	Stay planning
Istanbul	TRY 5,170,000 - 9,400,000+	USD 110,000 - 200,000+	Primary location to investigate major hematology, apheresis, cell-processing logistics, transplant, ICU, and research-program access.	This is a planning band only; require written product and program confirmation.
Ankara	TRY 5,170,000 - 9,400,000+	USD 110,000 - 200,000+	Major academic hematology and transplant expertise may support product-specific evaluation.	Confirm current commercial or study access directly with the cellular-therapy team.
Izmir	TRY 5,170,000 - 9,400,000+	USD 110,000 - 200,000+	Selected tertiary hematology programs may assess candidates or coordinate referral.	Do not infer on-site manufacturing or infusion from transplant capability.
Antalya	TRY 5,170,000 - 9,400,000+	USD 110,000 - 200,000+	International coordination may be available, but product-specific delivery requires explicit proof.	Hospitality experience does not establish cellular-therapy authorization.
Bursa	TRY 5,170,000 - 9,400,000+	USD 110,000 - 200,000+	Tertiary hematology may support records review and referral for selected patients.	Verify apheresis, manufacturer agreement, infusion, ICU, and follow-up at one program.
Kocaeli and Gebze	TRY 5,170,000 - 9,400,000+	USD 110,000 - 200,000+	Marmara location may support access to large centers and laboratory logistics.	Require the exact treating campus and chain-of-custody plan.
Adana	TRY 5,170,000 - 9,400,000+	USD 110,000 - 200,000+	Regional hematology assessment does not automatically mean CAR-T product availability.	Obtain direct program acceptance before travel.
Konya	TRY 5,170,000 - 9,400,000+	USD 110,000 - 200,000+	Referral and eligibility review may be more realistic than assuming local delivery.	Plan only after named-product and hospital confirmation.
Kayseri	TRY 5,170,000 - 9,400,000+	USD 110,000 - 200,000+	Selected academic hematology services may review disease and alternatives.	The range is not evidence of a manufacturing slot or certified program.
Gaziantep	TRY 5,170,000 - 9,400,000+	USD 110,000 - 200,000+	Hospital-level referral pathways and complex-care support require verification.	Do not pay an intermediary without direct cellular-therapy documentation.

Estimate variables

What can change the final hospital cost

Product and manufacturing contract

Target, manufacturer, commercial or study route, cell processing, quality release, shipping, taxes, currency, and cancellation terms dominate price.

A manufacturer slot should be documented.

Eligibility and disease burden

Pathology, marrow and imaging, previous treatment, disease speed, organ fitness, infection, and target status determine whether the pathway proceeds.

Reassessment may be needed before infusion.

Bridging treatment

Number, type, response, admission, radiation, transfusion, and complication of treatments during manufacturing vary widely.

Use a named bridge and backup plan.

Toxicity and critical care

CRS, ICANS, infection, prolonged cytopenia, organ injury, ICU, anti-cytokine medicine, steroids, and procedures can add major expense.

Obtain daily and high-cost drug rates.

Long monitoring horizon

Nearby stay, repeat laboratory and disease assessment, immunoglobulin, infection prevention, revaccination, and long-term reporting continue after discharge.

Confirm which care can transfer home.

Medical cost breakdown

Before admission, in hospital, and after discharge

Diagnostics and preparation

Disease confirmation and eligibility

Expert pathology, marrow, flow or molecular tests, target status where applicable, previous-treatment verification, and current response or progression assessment.

The product indication should be cited in the plan.

Restaging and organ fitness

PET-CT, CT, MRI, marrow, heart, lung, kidney, liver, neurologic, pregnancy, and performance evaluation as required by product or protocol.

Repeat tests may be required after bridging.

Infection and immune workup

Viral and other infectious screening, immunoglobulins, cultures or specialist review, dental or line assessment, and infection treatment before lymphodepletion.

Active infection may delay or prevent infusion.

Admission and treatment

Cell collection and manufacturing

Apheresis, line if needed, laboratory handling, cryopreservation, shipment, engineering, expansion, quality release, return shipping, and chain-of-identity controls.

Clarify failure and refund terms for every stage.

Conditioning and cellular infusion

Lymphodepleting chemotherapy, supportive care, product thaw and verification, infusion, ward monitoring, laboratory tests, transfusions, and infection prevention.

Ask whether admission begins before conditioning.

Toxicity rescue

CRS and neurotoxicity monitoring, anti-cytokine medicines, steroids, seizure support, oxygen, vasopressors, ICU, imaging, and organ support.

Severe care is rarely within a simple package ceiling.

Recovery and follow-up

Proximity monitoring

Frequent clinical and laboratory review near the treatment center after discharge, with a trained caregiver and rapid readmission route.

Ask for the required distance and number of days.

Blood and immune recovery

Transfusions, growth support, antimicrobial prevention, immunoglobulin, infection treatment, marrow checks, and revaccination planning.

Some needs continue for months.

Neurologic and disease follow-up

Cognitive and neurologic review, rehabilitation, PET-CT or marrow response assessment, relapse monitoring, and long-term product reporting.

Transfer complete records to the home hematologist.

Complete journey budget

Plan beyond the hospital invoice

Patient and attendant costs should be modeled separately from the medical estimate, with flexible dates and a contingency reserve.

Long, uncertain local stay

Evaluation, collection, manufacturing, bridging, conditioning, admission, and mandatory nearby monitoring can span many weeks.

Use flexible housing and flights rather than a short package.

Dedicated caregiver

A capable adult may need to remain throughout outpatient monitoring, recognize confusion and fever, manage medicines, and reach the hospital rapidly.

Include the caregiver’s visa, lodging, food, and lost work.

High-severity reserve

Manufacturing delay, disease progression, infection, ICU, prolonged low counts, extra lodging, alternate therapy, or medical transport can add substantial cost.

Review insurance exclusions and payment deposits.

Country access

Rules and practical requirements to verify

Visa, donor, fertility, medicine, licensing, and treatment-access requirements can change. Confirm current rules with the relevant authority and treating hospital.

Demand product and regulatory proof

Obtain the exact product or trial identifier, indication, Turkish authorization or ethics and protocol route, manufacturer or sponsor, and treating-center approval in writing.

Verify the cellular-therapy program

Confirm international-care authorization plus current hematology, apheresis, product handling, transfusion, infection, neurology, ICU, and long-term follow-up capability.

Document chain of identity and custody

The contract should identify responsibility for collection labeling, processing, cryopreservation, shipping, receipt, storage, product verification, and disposal.

Understand financial failure points

Ask what is payable or refundable if eligibility changes, collection fails, manufacturing is delayed or unsuccessful, disease progresses, product release fails, or infusion is cancelled.

Use official travel information

Check Turkish government visa guidance and plan for a clinically uncertain stay; medical fitness and program proximity rules may override a ticket date.

Hospital selection

Compare capability before package price

Named product access

Documented manufacturer or sponsor relationship, current slot, eligible indication, authorization route, product handling, and recent delivery experience.

A general oncology service is not enough.

Cellular-therapy multidisciplinary team

CAR-T hematologist, apheresis, cell laboratory and logistics, oncology pharmacy, infectious disease, neurology, intensive care, transfusion, and rehabilitation.

Ask who leads each phase and night-time emergencies.

CRS and ICANS readiness

Standard grading and treatment protocols, immediate anti-cytokine drug access, steroids, seizure management, imaging, ICU bed, and organ support.

Request the escalation route, not only a statement of availability.

Infection and cytopenia support

Protective care, microbiology, antimicrobials, immunoglobulin, blood products, marrow evaluation, and prolonged outpatient monitoring.

Confirm support after the package admission ends.

Transparent outcomes and contracts

Product-specific infusion, manufacturing failure, CRS and ICANS grade, ICU, early mortality, response, follow-up completeness, and financial terms.

No credible program guarantees remission.

Treating team

Specialists and support that may matter

CAR-T or cellular-therapy hematologist

Confirms product-specific eligibility, alternatives, collection timing, bridging, conditioning, infusion, toxicity management, and response assessment.

Apheresis and cell-logistics team

Plans vascular access, collection, labeling, chain of identity, processing, shipping, receipt, storage, and release coordination.

Neurology and intensive-care teams

Establish baseline function and manage ICANS, seizure, severe CRS, low oxygen, low blood pressure, and organ support.

Infectious-disease and transfusion specialists

Address screening, antimicrobial prevention, infection, immunoglobulin, blood products, and prolonged marrow suppression.

Home hematology team

Provides later blood and immune monitoring, infection response, transfusion access, revaccination, relapse assessment, and long-term reporting.

Treatment timeline

From report review to return-home follow-up

Remote product-specific screening

Send pathology, target and molecular results, previous treatment, response, imaging or marrow, organ tests, infections, transplant history, and performance.

Formal program evaluation

The cellular-therapy team verifies indication, product access, alternatives, fitness, manufacturing timeline, finances, caregiver, and home support.

Apheresis and manufacturing

Collect cells, maintain chain of identity, send for manufacturing and quality release, and monitor the patient while the product is prepared.

Bridging and pre-infusion reassessment

Control disease when needed, treat infection, repeat key tests, and confirm the patient remains eligible before lymphodepletion.

Conditioning, infusion, and acute monitoring

Give lymphodepleting chemotherapy, verify and infuse the product, and monitor closely for CRS, ICANS, infection, and cytopenias.

Nearby and home follow-up

Complete mandatory proximity monitoring, assess response, transfer toxicity and product records, and continue immune, blood, neurologic, and relapse surveillance.

Risks and edge cases

Events that can change the plan, stay, or cost

Manufacturing failure or delay

Collection may be inadequate or the product may not meet release criteria, while disease can progress during the wait.

Require backup treatment and financial terms before collection.

Cytokine release syndrome

Fever, low blood pressure, low oxygen, organ dysfunction, and rapid deterioration can require anti-cytokine treatment and ICU.

Use the program emergency protocol immediately.

Immune effector cell neurotoxicity

Confusion, handwriting or language change, weakness, tremor, seizure, or reduced consciousness can arise after infusion.

A caregiver should report subtle changes urgently.

Severe infection or prolonged cytopenia

Low immune cells and blood counts can lead to bacterial, viral, or fungal infection, bleeding, transfusions, and delayed recovery.

Confirm months of home support.

Disease progression before infusion

Rapid cancer growth or declining fitness can make the planned product unsafe or no longer useful after costs have begun.

Discuss decision points and alternatives in advance.

Destination comparison

Compare India, Turkey, and Thailand for this procedure

The most suitable destination depends on the individual case, required team, treatment availability, travel route, legal eligibility, budget, and continuity after returning home.

Procedure planning comparison across India, Turkey, and Thailand
Decision factor	India	Turkey	Thailand	How to use this
Verified commercial access	Product and center access is expanding but remains indication and program specific.	Current access must be confirmed directly for the exact product, authorization route, and hospital.	Availability is also limited and product-specific at selected centers.	Do not compare countries until written product access is established.
Manufacturing and logistics	Local or cross-border models vary by product and program.	Chain of identity, manufacturer agreement, shipment, and release route need explicit documentation.	International manufacturing may add timing and logistics complexity.	Compare collection-to-infusion time and failure terms.
Acute rescue capability	Major cellular and transplant centers can provide hematology, neurology, and ICU support.	Large academic and private hubs may provide integrated rescue when program-authorized.	Leading tertiary centers offer advanced critical care.	Product access without CRS and ICANS rescue is unacceptable.
Long-term continuity	Home-country distance varies and prolonged monitoring remains necessary.	Geography may help regional patients, but local stay can still be long.	Long flights can complicate early post-treatment return.	Choose based on program quality and home hematology, not tourism convenience.

Decision guidance

When Turkey may fit and when to keep comparing

Turkey may fit only when

The cellular-therapy program confirms eligibility, exact product and authorization, manufacturing slot, complete clinical and financial pathway, ICU rescue, caregiver rules, and home handover.

Continue comparing when

An intermediary promises generic CAR-T, cannot name the product or target, treats a price as proof of access, or omits manufacturing-failure and ICU terms.

Seek another expert review when

There is disagreement about indication, target, prior-line requirement, bridge, transplant alternative, infection, organ fitness, product access, or expected benefit.

Use immediate local care when

There is fever, low blood pressure, breathing difficulty, confusion, language or handwriting change, severe weakness, seizure, bleeding, or rapidly worsening illness.

Reports for review

Prepare a case file before requesting estimates

CAR-T screening needs complete pathology and disease subtype, target or molecular evidence where relevant, every previous treatment and response, current marrow and imaging, organ and infection tests, transplant history, neurologic baseline, medicines, function, and home-care capability. The file should be reviewed by the actual cellular-therapy program before any journey is booked.

Upload medical reports

Disease and prior treatment

Pathology and target evidence

Provide full reports, slides or blocks availability, flow, molecular data, and the result supporting the proposed product.

Treatment chronology

List every regimen, dose where available, dates, response, progression, toxicity, and transplant or radiation history.

Current disease burden

Send recent PET-CT, CT, MRI, marrow, laboratory markers, symptoms, and source files.

Alternative recommendations

Include transplant, trial, salvage, and supportive-care opinions already received.

Eligibility and safety

Blood and organ tests

Provide counts, kidney, liver, heart, lung, coagulation, performance, and protocol-specific assessments.

Infection and immune status

Include viral screening, cultures, recent infections, antimicrobial treatment, immunoglobulins, and vaccinations.

Neurologic baseline

Document seizure, stroke, neuropathy, cognition, handwriting, speech, movement, imaging, and neurologic medicines.

Access and collection history

Describe veins, central lines, prior apheresis, transfusions, and collection concerns.

Program and continuity

Product documentation

Name target, product, manufacturer or sponsor, indication, authorization or trial, slot, and expected manufacturing time.

Bridge and backup plan

Record proposed disease control, timing, expected effect, and what happens if manufacturing or eligibility fails.

Caregiver and local stay

Identify the adult caregiver, accommodation, transport, communication, finances, and proximity period.

Home hematology support

Confirm emergency admission, blood products, infection care, immunoglobulin, laboratory, imaging, and long-term follow-up.

Common questions

Questions about cost, travel, and follow-up

Is CAR-T currently available for every cancer in Turkey?

No. Access is product, target, indication, authorization, manufacturer, hospital, and time specific. The treating cellular-therapy program must confirm it in writing.

How much can CAR-T cost in Turkey?

A prudent pathway range is approximately TRY 5.17 million to 8.46 million, or USD 110,000 to 180,000, with severe toxicity or prolonged care potentially exceeding USD 200,000.

What does the product price include?

It may or may not include collection, shipping, manufacturing, quality release, conditioning, admission, toxicity medicines, ICU, and follow-up. Every component and exclusion needs a contract.

How long does manufacturing take?

Commercial CAR-T manufacturing commonly takes several weeks, but product, logistics, quality testing, scheduling, and unexpected delays change the interval.

What is bridging therapy?

It is cancer treatment used to maintain disease control between collection and CAR-T infusion. It can include medicines, radiation, or procedures and needs a separate budget.

What happens if manufacturing fails?

The program should explain whether collection can be repeated, which costs remain payable, refund terms, backup treatment, and how rapidly another plan can start.

Why is ICU access important?

Severe cytokine release syndrome, neurologic toxicity, infection, low blood pressure, low oxygen, seizure, or organ failure can require immediate intensive care.

Can I travel home immediately after discharge?

Usually a program requires the patient to remain nearby for a defined period with a responsible caregiver and rapid readmission access. Follow the product-specific rule.

Will CAR-T guarantee remission?

No. Some patients do not respond, relapse, cannot reach infusion, or experience serious toxicity. Expected benefit must be discussed for the exact disease and product.

Which symptoms are emergencies after CAR-T?

Fever, low blood pressure, breathing difficulty, confusion, speech or handwriting change, weakness, seizure, bleeding, or rapid deterioration requires immediate program-directed care.

Review and sources

How this guide was prepared

This is deliberately a pathway estimate rather than a claimed Turkish tariff. Current international CAR-T cost and Turkey market signals were normalized near TRY 47 per USD and organized around product access, eligibility, apheresis, cell logistics and manufacturing, bridging, lymphodepletion, infusion, ward and ICU care, CRS and ICANS, prolonged cytopenia, nearby monitoring, and home continuity. NCI and EMA sources support product-specific process and safety; Turkish Ministry resources support provider due diligence. No price signal was treated as evidence that a product or slot is available.

This guide is educational and does not confirm that any CAR-T product is available in Turkey, establish eligibility, replace a cellular-therapy program, predict response, or guarantee a price. Obtain written product, regulatory, manufacturer, program, financial, ICU, caregiver, and follow-up confirmation before travel or payment. Fever, low blood pressure, breathing difficulty, confusion, speech or handwriting change, weakness, seizure, bleeding, or rapid deterioration requires immediate emergency care.

Related planning